Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing to providing novel solutions for oncology, respiratory disease and other therapeutic areas by applying its proprietary Anticalin® technology to create differentiated drugs.
In 2017, Pieris forged strategic alliances with Servier and AstraZeneca to accelerate its transformation into a fully-integrated, biologics R&D and commercial organization, focused on two immunology-related therapeutic areas: immuno-oncology and respiratory disease. The foundation of Pieris' partnerships and R&D efforts is Anticalins®, a proprietary class of clinically-tested next generation therapeutic proteins.
Anticalin proteins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins can virtually bind to any target of interest